NRIX
NASDAQ · Biotechnology
Nurix Therapeutics Inc
$16.81
+0.11 (+0.66%)
Open$16.73
Previous Close$16.70
Day High$16.99
Day Low$16.20
52W High$22.50
52W Low$8.20
Volume—
Avg Volume820.1K
Market Cap1.68B
P/E Ratio—
EPS$-3.16
SectorBiotechnology
Analyst Ratings
Strong Buy
23 analysts
Price Target
+330.0% upside
Current
$16.81
$16.81
Target
$72.29
$72.29
$45.76
$72.29 avg
$82.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 97.04M | 74.91M | 234.23M |
| Net Income | -305,584,095 | -212,309,468 | -24,379,697 |
| Profit Margin | -314.9% | -299.2% | -10.4% |
| EBITDA | -319,995,038 | -234,672,908 | -31,389,191 |
| Free Cash Flow | — | — | -25,443,977 |
| Rev Growth | +29.5% | +29.5% | +16.3% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |